S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
NASDAQ:PRLD

Prelude Therapeutics (PRLD) Stock Price, News & Analysis

$5.62
+0.40 (+7.66%)
(As of 04/12/2024 08:52 PM ET)
Today's Range
$5.12
$5.77
50-Day Range
$2.68
$5.62
52-Week Range
$1.66
$8.56
Volume
58,000 shs
Average Volume
67,165 shs
Market Capitalization
$308.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.25

Prelude Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.67 Rating Score
Upside/​Downside
6.6% Downside
$5.25 Price Target
Short Interest
Healthy
1.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of Prelude Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.88) to ($1.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.63 out of 5 stars

Medical Sector

878th out of 929 stocks

Biotechnology Industry

28th out of 33 stocks

PRLD stock logo

About Prelude Therapeutics Stock (NASDAQ:PRLD)

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

PRLD Stock Price History

PRLD Stock News Headlines

Prelude Therapeutics (NASDAQ:PRLD) Trading Up 7.7%
The next wave of AI domination is emerging. The most explosive gains could come from these 4 stocks
2024 could be a challenging year. AI will continue creating profit opportunities (in some surprising new ways), but global conflict, divisive politics and not-yet-tamed inflation could bring uncertainty.
Prelude Therapeutics Inc Ordinary Shares PRLD
PRLD Apr 2024 5.000 call
The next wave of AI domination is emerging. The most explosive gains could come from these 4 stocks
2024 could be a challenging year. AI will continue creating profit opportunities (in some surprising new ways), but global conflict, divisive politics and not-yet-tamed inflation could bring uncertainty.
Prelude Therapeutics Incorporated Registered Shs
Q3 2023 Abcellera Biologics Inc Earnings Call
See More Headlines
Receive PRLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
4/14/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:PRLD
Fax
N/A
Employees
128
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.25
High Stock Price Target
$7.00
Low Stock Price Target
$4.00
Potential Upside/Downside
-6.6%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

Net Income
$-121,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.32 per share

Miscellaneous

Free Float
11,237,000
Market Cap
$308.65 million
Optionable
Optionable
Beta
1.51
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Krishna Vaddi D.V.M. (Age 58)
    Ph.D., Founder, CEO & Director
    Comp: $805.91k
  • Dr. Edna Huang M.D. (Age 51)
    President & Chief Medical Officer
    Comp: $563.55k
  • Dr. Peggy A. Scherle Ph.D. (Age 63)
    Chief Scientific Officer
    Comp: $868.62k
  • Mr. Laurent Chardonnet M.B.A. (Age 59)
    Chief Financial Officer
  • Ms. Aimee Crombie Ph.D.
    Senior VP and Head of Strategic Planning & Operations
  • Dr. Madhu Pudipeddi Ph.D.
    Senior Vice President of Technical Operations
  • Lindsey Trickett
    Vice President of Investor Relations
  • Mr. Bryant David Lim J.D. (Age 53)
    Chief Legal Officer & Corporate Secretary
  • Ms. Michele Porreca M.B.A.
    Chief People Officer
  • Dr. Andrew P. Combs Ph.D. (Age 58)
    Executive VP & Head of Chemistry
    Comp: $562.46k

PRLD Stock Analysis - Frequently Asked Questions

Should I buy or sell Prelude Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prelude Therapeutics in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" PRLD shares.
View PRLD analyst ratings
or view top-rated stocks.

What is Prelude Therapeutics' stock price target for 2024?

3 analysts have issued twelve-month target prices for Prelude Therapeutics' stock. Their PRLD share price targets range from $4.00 to $7.00. On average, they expect the company's stock price to reach $5.25 in the next twelve months. This suggests that the stock has a possible downside of 6.6%.
View analysts price targets for PRLD
or view top-rated stocks among Wall Street analysts.

How have PRLD shares performed in 2024?

Prelude Therapeutics' stock was trading at $4.27 at the start of the year. Since then, PRLD shares have increased by 31.6% and is now trading at $5.62.
View the best growth stocks for 2024 here
.

When is Prelude Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our PRLD earnings forecast
.

How were Prelude Therapeutics' earnings last quarter?

Prelude Therapeutics Incorporated (NASDAQ:PRLD) posted its earnings results on Thursday, February, 15th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.03.

When did Prelude Therapeutics IPO?

Prelude Therapeutics (PRLD) raised $149 million in an initial public offering on Friday, September 25th 2020. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities served as the underwriters for the IPO.

How do I buy shares of Prelude Therapeutics?

Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRLD) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners